Navigation Links
Hodgkin lymphoma survivors have increased risk of stroke and transient ischemic attack
Date:6/17/2009

Patients treated for Hodgkin lymphoma with radiation therapy have a substantially higher risk of stroke, according to a new study published June 17 online in the Journal of the National Cancer Institute.

The study was undertaken because information on clinically verified stroke and transient ischemic attack (TIA), or a "mini stroke," following Hodgkin lymphoma is limited.

In order to quantify the long-term risks, Flora E. van Leeuwen, Ph.D., of the Department of Epidemiology at the Netherlands Cancer Institute in Amsterdam, and colleagues performed a retrospective cohort study among 2,201 Hodgkin lymphoma survivors. The patients, who had survived at least 5 years from the time of diagnosis, had been treated between 1965 and 1995 before age 51. The researchers compared incidence rates of clinically verified stroke and TIA in this cohort with rates in the general population.

After a median follow-up of almost 18 years, 96 patients developed cerebrovascular disease. The incidence rate for stroke was 2.2 times the incidence in the general population. For TIA, it was 3.1. Risks also remained elevated, compared to those in the general population, after prolonged follow-up. Radiation to the neck and mediastinum was associated with increased risk, whereas chemotherapy was not.

"For young survivors of Hodgkin lymphoma, who are at especially increased risk of stroke and TIA, physicians should consider appropriate risk-reducing strategies, such as treatment of hypertension and lifestyle changes to reduce the risk of stroke and TIA," the authors write.

In an accompanying editorial, Dan L. Longo, M.D., of the National Institute on Aging, part of the National Institutes of Health in Bethesda, Md., discusses the study's contribution to the "already overwhelming evidence that radiation therapy in Hodgkin's disease is short-sighted" He applauds the detailed medical documentation and nearly complete follow-up of the patients in the study, but notes a weakness, in that the relationship of stroke to radiation doses was not examined.

According to Longo, results of this study should affect a physician's choice of primary treatment. "Unfortunately, given the life-long increased risks of late effects that have been documented from the use of radiation therapy, we simply cannot keep exposing patients to risk without clear benefit while we wait for safety data to be produced," he writes. "With an alternative therapy at hand that is just as effective, it is simply unjustified to keep using a toxic modality for the next 10-20 years"


'/>"/>

Contact: Steve Graff
jncimedia@oxfordjournals.org
301-841-1285
Journal of the National Cancer Institute
Source:Eurekalert

Related medicine news :

1. Radiation May Raise Stroke Risk After Hodgkins
2. Pixantrone Overview in Non-Hodgkins Lymphoma to be Presented at 2009 Pan Pacific Lymphoma Conference
3. Medarex Announces Clinical Data for MDX-1401 in Hodgkins Lymphoma at Annual Meeting of the American Association for Cancer Research
4. New NCCN Guidelines for Primary Cutaneous B-Cell Lymphoma and Updates to NCCN Guidelines for Non-Hodgkins Lymphomas
5. DNA Variations May Alter Risk of Hodgkins Disease
6. DNA differences may influence risk of Hodgkin disease
7. Hodgkins Survivors Prone to Breast Cancer Later
8. Pediatric Hodgkins disease survivors face increased breast cancer risk
9. Three Italian Multicenter Studies Report High (>70%) Rates of Complete Remission (CR) Utilizing Zevalin Radio-Immunotherapy (RIT) in Treatment of Newly Diagnosed or Relapsed or Refractory Non-Hodgkins Lymphoma
10. Video: Cephalon Receives FDA Approval for TREANDA to Treat Patients with Relapsed Indolent Non-Hodgkins Lymphoma
11. Cephalon Receives FDA Approval for TREANDA to Treat Patients with Relapsed Indolent Non-Hodgkins Lymphoma
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/24/2016)... , ... June 24, 2016 , ... Global law firm ... 2016 Legal Elite. The attorneys chosen by their peers for this recognition are considered ... Seven Greenberg Traurig Shareholders received special honors as members of this year’s Legal Elite ...
(Date:6/24/2016)... ... June 24, 2016 , ... Comfort Keepers® of San Diego, CA is ... Road To Recovery® program to drive cancer patients to and from their cancer treatments. ... the highest quality of life and ongoing independence. Getting to and from medical ...
(Date:6/24/2016)... ... June 24, 2016 , ... People across the U.S. are ... Code Talker Award, an essay contest in which patients and their families pay tribute ... presented at the 2016 National Society of Genetic Counselors (NSGC) Annual Education Conference (AEC) ...
(Date:6/24/2016)... , ... June 24, 2016 , ... ... is proud to recognize Dr. Barry M. Weintraub as a prominent plastic surgeon ... beautiful women in the world, and the most handsome men, look naturally attractive. ...
(Date:6/24/2016)... ... 2016 , ... Strategic Capital Partners, LLC (SCP) in concert ... capital for emerging technology companies. SCP has delivered investment events and professional ... than a million dollars of capital investment for five companies. The ...
Breaking Medicine News(10 mins):
(Date:6/23/2016)... , June 23, 2016  In a startling report released today, ... their residents by lacking a comprehensive, proven plan to eliminate prescription ... definitive ranking of how states are tackling the worst drug crisis ... four states – Kentucky , New ... Vermont . Of the 28 failing states, three – ...
(Date:6/23/2016)... -- Research and Markets has announced the addition ... - Forecast to 2022" report to their offering. ... to date financial data derived from varied research sources to ... potential impact on the market during the next five years, ... of sub markets, regional and country level analysis. The report ...
(Date:6/23/2016)... 2016 Research and Markets has announced ... report to their offering. ... a favourable commercial environment for MedImmune to enter. The US ... will serve to drive considerable growth for effective anti-influenza medications. ... cap sales considerably, but development is still in its infancy. ...
Breaking Medicine Technology: